Reason for optimism
Reason for optimism
Peter Doshi

BMJ 2008;336;172-
doi:10.1136/bmj.39465.484421.3A

Updated information and services can be found at:
http://bmj.com/cgi/content/full/336/7637/172

These include:

References
This article cites 3 articles, 2 of which can be accessed free at:
http://bmj.com/cgi/content/full/336/7637/172#BIBL

Rapid responses
You can respond to this article at:
http://bmj.com/cgi/eletter-submit/336/7637/172

Email alerting service
Receive free email alerts when new articles cite this article - sign up in the box at the top left of the article

Notes

To order reprints follow the "Request Permissions" link in the navigation box
To subscribe to BMJ go to:
http://resources.bmj.com/bmj/subscribers
COMPETING INTERESTS
Technology, Cambridge, MA, USA

PHOTO: PAUL J MARSH

MISSING FACTS, DIFFERENT COUNTRIES
Blagg states that home haemodialysis (HD) is cost effective.1 In the United States, where there is less likelihood of receiving a cadaveric transplant than in the United Kingdom (45% v 30%), the economics are different. In the United Kingdom the break even point on the set up and running costs of home HD v in-centre HD is about two years. Analysis of data from the UK Renal Registry shows that within 20 months of starting, half of the patients receiving home HD would have received a kidney transplant. This makes the cost neutral point towards 3-4 years.

It will always be difficult to show that home HD improves survival as patients on the home HD programme in any renal unit are always highly selected. They are unlikely to have any comorbid conditions and have good fistulas (not central lines). It is difficult even with age matching to allow for all these selection factors in matching a similar cohort.

Short daily dialysis is a separate (and more costly) entity than standard home HD requiring specific equipment and is currently undergoing evaluation in the UK.

The high rates of home HD in New Zealand are related to some specific factors in their healthcare system but do not imply a free choice. The UK also has a larger peritoneal dialysis programme than the US and other EU countries. In those countries some patients receiving home HD may rather have chosen peritoneal dialysis. All these factors increase the complexity of any international comparison.

David Ansell director, UK Renal Registry, Southmead Hospital, Bristol BS10 5 NB david.ansell@nbt.nhs.uk

Author’s reply
Selection bias has an important role, but almost all reports on quality of life have shown the benefits of home haemodialysis (HD), and patients are vocal about the advantages they have experienced. Even if survival is no better, surely willing and suitable patients should have access to a treatment that provides, for example, opportunity for longer or more frequent dialysis, improved quality of life, rehabilitation, and flexibility of scheduling?

In terms of urbanisation, Australia ranks 19th in the world (91% urbanisation) compared with the UK, which is 20th (90% urbanisation), and New Zealand, which is 32nd (86% urbanisation).1 On the basis of their registries, the rates per million for HD, peritoneal dialysis, and transplantation are also similar—303, 85, and 317 in the UK; 330, 88, and 322 in Australia; and 277, 176, and 302 in New Zealand.

1 Blagg CR. Home haemodialysis. BMJ 2008;336:3-4. (5 January.)

Author’s reply
Selection bias has an important role, but almost all reports on quality of life have shown the benefits of home haemodialysis (HD), and patients are vocal about the advantages they have experienced. Even if survival is no better, surely willing and suitable patients should have access to a treatment that provides, for example, opportunity for longer or more frequent dialysis, improved quality of life, rehabilitation, and flexibility of scheduling.

In terms of urbanisation, Australia ranks 19th in the world (91% urbanisation) compared with the UK, which is 20th (90% urbanisation), and New Zealand, which is 32nd (86% urbanisation). On the basis of their registries, the rates per million for HD, peritoneal dialysis, and transplantation are also similar—303, 85, and 317 in the UK; 330, 88, and 322 in Australia; and 277, 176, and 302 in New Zealand.

1 Blagg CR. Home haemodialysis. BMJ 2008;336:3-4. (5 January.)